Get the Stockscreener App
1.73
4.95%
-0.09
After Hours:
1.72
-0.01
-0.58%
Nrx Pharmaceuticals Inc stock is traded at $1.73, with a volume of 348.70K.
It is down -4.95% in the last 24 hours and down -22.07% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$1.82
Open:
$1.84
24h Volume:
348.70K
Relative Volume:
0.39
Market Cap:
$51.22M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.4325
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
+2.98%
1M Performance:
-22.07%
6M Performance:
-27.62%
1Y Performance:
-41.16%
1-Day Range:
$1.70
$1.84
1-Week Range:
$1.70
$1.995
52-Week Range:
$1.58
$3.84
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
1.73 | 53.88M | 0 | -30.15M | -21.66M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
Is NRx Pharmaceuticals Inc. stock a buy before product launchesWeekly Loss Report & Technical Confirmation Alerts - mfd.ru
Market Recap: Can NRx Pharmaceuticals Inc Equity Warrant weather a recessionRisk Management & Verified Entry Point Detection - baoquankhu1.vn
Inflation Data: Is NRx Pharmaceuticals Inc. Equity Warrant likely to announce a buybackMarket Growth Summary & Weekly Momentum Picks - baoquankhu1.vn
Aug Gainers: Will NRx Pharmaceuticals Inc stock hit new highs in YEARJuly 2025 Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
NRx Pharmaceuticals appoints Joseph M. Casper as chief operating officer By Investing.com - Investing.com Australia
NRx Pharmaceuticals appoints Joseph M. Casper as chief operating officer - Investing.com
FDA fast track puts ketamine-based therapy in spotlight for suicide care - MSN
Market Review: Can NRx Pharmaceuticals Inc Equity Warrant maintain its current growth rateEarnings Overview Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Published on: 2026-01-31 19:02:41 - baoquankhu1.vn
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Increase in Short Interest - MarketBeat
NRx Pharmaceuticals completes debt repayment, ends 2025 debt-free - MSN
NRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Lowered by Zacks Research - MarketBeat
Movement Recap: How does NRx Pharmaceuticals Inc perform in inflationary periodsSwing Trade & Real-Time Stock Entry Alerts - baoquankhu1.vn
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Volatility Watch: How volatile is NRx Pharmaceuticals Inc Equity Warrant stockPortfolio Return Summary & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Breakout Zone: Should value investors consider Sprouts Farmers Market IncInsider Buying & Real-Time Stock Entry Alerts - baoquankhu1.vn
What is the dividend yield of NRx Pharmaceuticals Inc. Equity Warrant2025 Geopolitical Influence & Weekly High Return Stock Opportunities - mfd.ru
NRx Pharmaceuticals (NASDAQ: NRXP) sets virtual annual meeting for March - MSN
Aug Catalysts: Is NRx Pharmaceuticals Inc Equity Warrants growth already priced inQuarterly Trade Summary & AI Optimized Trading Strategy Guides - baoquankhu1.vn
NRx Pharmaceuticals (NASDAQ: NRXP) Sets Virtual Annual Meeting for March - mychesco.com
FDA Fast Track Puts Ketamine-Based Therapy in Spotlight for Suicide Care - mychesco.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP) and Qiagen (QGEN) - The Globe and Mail
H.C. Wainwright reiterates Buy rating on NRx Pharmaceuticals stock at $40 - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on NRx Pharmaceuticals stock at $40 By Investing.com - Investing.com India
Short Squeeze: What is the dividend yield of NRx Pharmaceuticals IncPortfolio Gains Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Pullback Watch: Can GRDN withstand a market correctionTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
NRXP Stock: Ascendiant Capital Raises Price Target to $48 | NRXP - GuruFocus
NRx Pharmaceuticals Addresses Nasdaq Meeting Compliance Requirements - The Globe and Mail
Milestone Patient Data Eclipsing 70,000 on Real World Use - openPR.com
NRx Pharmaceuticals Received Notice of Noncompliance - TradingView
NRx Pharmaceuticals Announces 2025 Annual Meeting Date and Record Date - citybiz
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date - The Manila Times
Sentiment Review: What are NRx Pharmaceuticals Incs recent SEC filings showingPortfolio Return Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
NRx Pharmaceuticals Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be submitted to the FDA in Support of NRX-100 Approval - marketscreener.com
Biotech NRx Pharma outlines its business at H.C. Wainwright investor event - Stock Titan
NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at BTIG Research - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval - Sahm
Milestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
FinancialContentMilestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
NRx Pharmaceuticals (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100 - Digital Journal
NRx Pharmaceuticals Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression - citybiz
NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset - TechStock²
About Us - FinancialContent
NRx Pharma Strengthens NRX-100 Approval Case With 70,000-Patient Real-World Ketamine Data - Nasdaq
Why Did NRXP Stock Surge 21% Pre-Market Today? - Stocktwits
NRx Pharmaceuticals' NRX-100 Receives FDA Fast Track Designation for Treatment of Suicidal Ideation in Depression and Bipolar Depression - Quiver Quantitative
Is NRx Pharmaceuticals Inc backed by strong institutional buying2025 Sector Review & Verified Stock Trade Ideas - baoquankhu1.vn
Earnings Report: Should I hold or sell NRx Pharmaceuticals Inc Equity Warrant stock in 2025Quarterly Trade Review & Daily Oversold Bounce Ideas - Bộ Nội Vụ
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):